In Vitro Evaluation of a Novel Chemotherapeutic Agent, Adozelesin, in Gynecologic-cancer Cell Lines

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1992 Jan 1

PMID 1586978

Authors

H N Nguyen

B U Sevin

H Averette

J Perras

R Hightower

R Ramos

D Donato

M Penalver

Affiliations

Soon will be listed here.

Abstract

Adozelesin is a derivative of an extremely cytotoxic compound, CC1065. This entirely new class of drug binds preferentially to DNA and facilitates alkylation reaction. In the present study, we used the adenosine triphosphate (ATP) chemosensitivity assay to compare the cytotoxic potency of Adozelesin with that of common chemotherapeutic agents in ten gynecologic-cancer cell lines. Flow cytometry was also used to study its effects on cell-cycle kinetics. The mean drug concentrations required to produce a 50% reduction in ATP levels as compared with controls [IC50] were: Adriamycin, 0.17 +/- 0.06 microM; 4OH-Cytoxan, 18 +/- 3 microM; cisplatin, 17 +/- 7 microM; 5-fluorouracil, 183 +/- 116 microM; and Adozelesin, 11.0 +/- 5.4 pM. Thus, Adozelesin was 10(4) - 10(7) times more potent than Adriamycin, cisplatin, 5-fluorouracil, and Cytoxan. Cell kinetics studies revealed significant S and G2 blocks such as those previously reported for other alkylating agents.

References

Martin D, Biles C, GERPHEIDE S, HANKA L, KRUEGER W, McGovren J . CC-1065 (NSC 298223), a potent new antitumor agent improved production and isolation, characterization and antitumor activity. J Antibiot (Tokyo). 1981; 34(9):1119-25. DOI: 10.7164/antibiotics.34.1119. View

Geisinger K, Kute T, Pettenati M, Welander C, Dennard Y, Collins L . Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors. Cancer. 1989; 63(2):280-8. DOI: 10.1002/1097-0142(19890115)63:2<280::aid-cncr2820630213>3.0.co;2-n. View

Warpehoski M, Gebhard I, Kelly R, KRUEGER W, Li L, McGovren J . Stereoelectronic factors influencing the biological activity and DNA interaction of synthetic antitumor agents modeled on CC-1065. J Med Chem. 1988; 31(3):590-603. DOI: 10.1021/jm00398a017. View

Kingston R, Sevin B, Ramos R, Saks M, Donato D, Jarrell M . Synergistic effects of cis-platinum and cytosine arabinoside on ovarian carcinoma cell lines, demonstrated by dual-parameter flow cytometry. Gynecol Oncol. 1989; 32(3):282-7. DOI: 10.1016/0090-8258(89)90625-2. View

McGovren J, Clarke G, PRATT E, DeKoning T . Preliminary toxicity studies with the DNA-binding antibiotic, CC-1065. J Antibiot (Tokyo). 1984; 37(1):63-70. DOI: 10.7164/antibiotics.37.63. View

Bertelsen C, Sondak V, Mann B, Korn E, Kern D . Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations. Cancer. 1984; 53(6):1240-5. DOI: 10.1002/1097-0142(19840315)53:6<1240::aid-cncr2820530604>3.0.co;2-y. View

Ichihashi H, Nogaki M, Yamauchi M, Takagi H, Kondo T, Ozawa T . A simple and rapid in vitro test for determining sensitivity of cancer cells to anticancer drugs. Jpn J Surg. 1986; 16(5):380-3. DOI: 10.1007/BF02470564. View

Chou T, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55. DOI: 10.1016/0065-2571(84)90007-4. View

Anai H, Maehara Y, Kusumoto H, Sugimachi K . Comparison of the chemosensitivity of human neoplastic tissues between succinate dehydrogenase inhibition test and ATP assay. Clin Chim Acta. 1987; 166(1):107-9. DOI: 10.1016/0009-8981(87)90204-x. View

10.

Maehara Y, Anai H, Tamada R, Sugimachi K . The ATP assay is more sensitive than the succinate dehydrogenase inhibition test for predicting cell viability. Eur J Cancer Clin Oncol. 1987; 23(3):273-6. DOI: 10.1016/0277-5379(87)90070-8. View

11.

Garewal H, Ahmann F, Schifman R, Celniker A . ATP assay: ability to distinguish cytostatic from cytocidal anticancer drug effects. J Natl Cancer Inst. 1986; 77(5):1039-45. View

12.

Kuzmits R, Rumpold H, Muller M, Schopf G . The use of bioluminescence to evaluate the influence of chemotherapeutic drugs on ATP-levels of malignant cell lines. J Clin Chem Clin Biochem. 1986; 24(5):293-8. DOI: 10.1515/cclm.1986.24.5.293. View

13.

Sevin B, Peng Z, Perras J, Ganjei P, Penalver M, AVERETTE H . Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol Oncol. 1988; 31(1):191-204. DOI: 10.1016/0090-8258(88)90293-4. View

14.

Nogaki M, Ichihashi H . [A new chemosensitivity test for cancer cells by measuring intracellular ATP content]. Nihon Geka Gakkai Zasshi. 1988; 89(12):1950-6. View

15.

Wierenga W, Bhuyan B, Kelly R, KRUEGER W, Li L, McGovren J . Antitumor activity and biochemistry of novel analogs of the antibiotic, CC-1065. Adv Enzyme Regul. 1986; 25:141-55. DOI: 10.1016/0065-2571(86)90012-9. View

16.

Petru E, Sevin B, Perras J, Boike G, Ramos R, Nguyen H . Comparative chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP bioluminescence. Gynecol Oncol. 1990; 38(2):155-60. DOI: 10.1016/0090-8258(90)90032-g. View

17.

Saeki T, Jinushi K, Kim R, Kirihara Y, Takagami S, Nishiyama M . [Comparison of succinic dehydrogenase inhibition test with adenosine triphosphate inhibition assay for human solid tumors as in vitro chemosensitivity tests]. Gan To Kagaku Ryoho. 1989; 16(5):2025-30. View

18.

Swenson D, Li L, Hurley L, Rokem J, Petzold G, Dayton B . Mechanism of interaction of CC-1065 (NSC 298223) with DNA. Cancer Res. 1982; 42(7):2821-8. View

19.

Nguyen H, Sevin B, AVERETTE H, Perras J, Ramos R, Penalver M . The effects of Provera on chemotherapy of uterine cancer cell lines. Gynecol Oncol. 1991; 42(2):165-77. DOI: 10.1016/0090-8258(91)90339-7. View

20.

Von Hoff D, Casper J, Bradley E, Sandbach J, Jones D, Makuch R . Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med. 1981; 70(5):1027-41. DOI: 10.1016/0002-9343(81)90859-7. View